Scancell Holdings Plc Hardman Report: New frontiers in T-cell activation
September 26 2016 - 1:15AM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
26 September 2016
Hardman Research: New frontiers in T-cell activation
New frontiers in T-cell activation and targeting: Scancell is a
clinical stage pharmaceutical company developing two distinct
flexible cancer immunotherapy platforms, each with broad
applications. ImmunoBody is a DNA vaccine which stimulates high
avidity anti-tumour T-cells for use as a monotherapy or in
combination with checkpoint inhibitors. Moditope targets modified
antigens and stimulates powerful anti-tumour T-cell responses for
use in advanced and hard-to-treat cancers. Both platforms are
targeting multi-billion dollar markets. The recent capital increase
will be used to advance both platforms to the next stage of
development and investment in corporate infrastructure.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/scancell-documents/26.09.16-new-frontiers-in-t-cell-activation-and-targeting.pdf
To contact us: Contact: Dr Martin Hall
Hardman & Co mh@hardmanandco.com
11/12 Tokenhouse Dr Dorothea Hill
Yard dmh@hardmanandco.com
London Dr Gregoire Pave
EC2R 7AS gp@hardmanabdco.com
Telephone: +44 20 7929 3399
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASEEFIDFMSEIU
(END) Dow Jones Newswires
September 26, 2016 02:15 ET (06:15 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024